These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 21300591)

  • 1. GAVI takes steps to address funding woes.
    Usher AD
    Lancet; 2011 Feb; 377(9764):453. PubMed ID: 21300591
    [No Abstract]   [Full Text] [Related]  

  • 2. GAVI enters its second decade with massive funding gap.
    Usher AD
    Lancet; 2010 Mar; 375(9717):791. PubMed ID: 20217910
    [No Abstract]   [Full Text] [Related]  

  • 3. GAVI's funding challenge.
    Lob-Levyt J
    Lancet; 2010 May; 375(9727):1692-3. PubMed ID: 20472166
    [No Abstract]   [Full Text] [Related]  

  • 4. GAVI's challenges: funding and leadership.
    Lancet; 2010 Oct; 376(9751):1438. PubMed ID: 21036259
    [No Abstract]   [Full Text] [Related]  

  • 5. Dagfinn Høybråten-new Board Chair of GAVI Alliance.
    Shetty P
    Lancet; 2011 Feb; 377(9764):459. PubMed ID: 21296226
    [No Abstract]   [Full Text] [Related]  

  • 6. Making new vaccines affordable: a comparison of financing processes used to develop and deploy new meningococcal and pneumococcal conjugate vaccines.
    Hargreaves JR; Greenwood B; Clift C; Goel A; Roemer-Mahler A; Smith R; Heymann DL
    Lancet; 2011 Nov; 378(9806):1885-93. PubMed ID: 21664678
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tracking donor funding towards achieving the Global Vaccine Action Plan (GVAP) goals: A landscape analysis (1990-2016).
    Ikilezi G; Zlavog B; Augusto OJ; Sherr K; Lim SS; Dieleman JL
    Vaccine; 2018 Nov; 36(49):7487-7495. PubMed ID: 30366804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Global alliance for vaccines and immunization (GAVI).
    Indian J Med Sci; 2001 Nov; 55(11):635-9. PubMed ID: 12508637
    [No Abstract]   [Full Text] [Related]  

  • 9. Projected health and economic impact of rotavirus vaccination in GAVI-eligible countries: 2011-2030.
    Atherly DE; Lewis KD; Tate J; Parashar UD; Rheingans RD
    Vaccine; 2012 Apr; 30 Suppl 1():A7-14. PubMed ID: 22520139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GAVI rolls out vaccines against child killers to more countries.
    Moszynski P
    BMJ; 2011 Sep; 343():d6217. PubMed ID: 21957215
    [No Abstract]   [Full Text] [Related]  

  • 11. Insights from global data for use of rotavirus vaccines in India.
    Rao TS; Arora R; Khera A; Tate JE; Parashar U; Kang G;
    Vaccine; 2014 Aug; 32 Suppl 1():A171-8. PubMed ID: 25091672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Projected health benefits and costs of pneumococcal and rotavirus vaccination in Uganda.
    Tate JE; Kisakye A; Mugyenyi P; Kizza D; Odiit A; Braka F
    Vaccine; 2011 Apr; 29(17):3329-34. PubMed ID: 21241733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability?
    Lydon P; Levine R; Makinen M; Brenzel L; Mitchell V; Milstien JB; Kamara L; Landry S
    Vaccine; 2008 Dec; 26(51):6706-16. PubMed ID: 18952134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The GAVI Alliance--successes and ongoing challenges.
    Lancet; 2013 Oct; 382(9901):1310. PubMed ID: 24139109
    [No Abstract]   [Full Text] [Related]  

  • 15. The GAVI Financing Task Force: one model of partner collaboration.
    Milstien JB; Kamara L; Lydon P; Mitchell V; Landry S
    Vaccine; 2008 Dec; 26(51):6699-705. PubMed ID: 19306508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten years of the Global Alliance for Vaccines and Immunization: challenges and progress.
    Clemens J; Holmgren J; Kaufmann SH; Mantovani A
    Nat Immunol; 2010 Dec; 11(12):1069-72. PubMed ID: 21079627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Financial challenges of immunization: a look at GAVI.
    Kaddar M; Lydon P; Levine R
    Bull World Health Organ; 2004 Sep; 82(9):697-702. PubMed ID: 15628208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High cost is the primary barrier reported by physicians who prescribe vaccines not included in India's Universal Immunization Program.
    Kahn GD; Thacker D; Nimbalkar S; Santosham M
    J Trop Pediatr; 2014 Aug; 60(4):287-91. PubMed ID: 24567310
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Financing vaccinations - the South African experience.
    Blecher MS; Meheus F; Kollipara A; Hecht R; Cameron NA; Pillay Y; Hanna L
    Vaccine; 2012 Sep; 30 Suppl 3():C79-86. PubMed ID: 22939027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs of diarrheal disease and the cost-effectiveness of a rotavirus vaccination program in kyrgyzstan.
    Flem ET; Latipov R; Nurmatov ZS; Xue Y; Kasymbekova KT; Rheingans RD
    J Infect Dis; 2009 Nov; 200 Suppl 1():S195-202. PubMed ID: 19817600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.